Single-cell Epigenome Analysis of the Alzheimer's Disease Brain
Award amount
$1,959,866Program and phase
SBIR · Phase IIAward year
2024Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EPIGENOME TECHNOLOGIES, INC.
- Proposal award date
- 2024-09-20
- Contract end date
- 2026-05-31
- UEI
- LS7JQN77JKQ1
- Solicitation number
- PAS22-196
- Topic code
- NIA
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- High-throughput Single Cell Co-assay of Histone Modifications andTranscriptome
- Single-cell Epigenome Analysis of the Alzheimer's Disease Brain
- Broadly Accessible Technologies for Single-cell Joint Analysis of Transcriptome and Epigenome
- High-throughput Single Cell Co-assay of Histone Modifications and Transcriptome
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Research funding history
5 SBIR/STTR records share this UEI (2021–2024). Reported award amounts total $5,662,517. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services